ARNA:NSD-Arena Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 77.68

Change

0.00 (0.00)%

Market Cap

USD 4.52B

Volume

0.48M

Average Target Price

USD 95.77 (+23.29%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Address: 6154 Nancy Ridge Drive, San Diego, CA, United States, 92121

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD61.78B 23.28 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

USD57.38B 19.71 14.64
MRNA Moderna, Inc

N/A

USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

N/A

USD34.10B N/A N/A
SGEN Seagen Inc

N/A

USD32.71B 69.01 70.76
RPRX Royalty Pharma plc

N/A

USD31.99B 22.60 11.58
GMAB Genmab A/S

N/A

USD28.33B 26.59 3.19
BNTX BioNTech SE

N/A

USD26.11B -99,999.99 N/A
INCY Incyte Corporation

N/A

USD21.44B 47.64 35.20

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.74 %

N/A

USD0.16B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

N/A

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

N/A

N/A
ROSC Hartford Multifactor Smal.. 0.00 % 0.34 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.11% 21% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.11% 21% F 26% F
Trailing 12 Months  
Capital Gain 74.52% 69% D+ 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.52% 69% D+ 79% C+
Trailing 5 Years  
Capital Gain 370.79% 86% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 370.79% 86% B 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 49.88% 79% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.88% 79% C+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 63.54% 41% F 19% F
Risk Adjusted Return 78.50% 95% A 87% B+
Market Capitalization 4.52B 90% A- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 48% F 81% B-
Price/Book Ratio 4.00 61% D- 40% F
Price / Cash Flow Ratio 7.94 9% F 41% F
EV/EBITDA 3.52 40% F 88% B+
Management Effectiveness  
Return on Equity -32.03% 78% C+ 29% F
Return on Invested Capital 42.02% 94% A 96% A
Return on Assets -19.13% 68% D+ 20% F
Debt to Equity Ratio 4.26% 72% C- 83% B
Technical Ratios  
Short Ratio 6.55 26% F 17% F
Short Percent 6.55% 49% F 32% F
Beta 0.83 78% C+ 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.